Challenges for accurate susceptibility testing, detection and interpretation of β-lactam resistance phenotypes in pseudomonas aeruginosa: Results from a spanish multicentre study

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 3, 2013, Pages 619-630

  Juan, Carlos ^a   Conejo, M Carmen ^b   Tormo, Nuria ^c   Gimeno, Concha ^c   Pascual, Álvaro ^b,d   Oliver, Antonio ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

AmpC; Carbapenemases; Efflux pumps; Extended spectrum lactamases; Metallo lactamases

Indexed keywords

AZTREONAM; BETA LACTAM; CARBAPENEMASE; PIPERACILLIN PLUS TAZOBACTAM;

ACCURACY; ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; CONCENTRATION RESPONSE; DESCRIPTIVE RESEARCH; HOSPITAL MANAGEMENT; INFECTION CONTROL; LABORATORY; LABORATORY DEVICE; LABORATORY TEST; NONHUMAN; PHENOTYPE; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; HUMANS; LABORATORY PROFICIENCY TESTING; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PSEUDOMONAS AERUGINOSA; SPAIN;

EID: 84873587593     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks439     Document Type: Article

References (52)

1. Vincent JL. Nosocomial infections in adult intensive-care units. Lancet 2003; 361: 2068-77.
2. Lyczak JB, Cannon CL, Pier GB. Lung infection associated with cystic fibrosis. Clin Microbiol Rev 2002; 15: 194-222.
3. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009; 22: 582-610.
4. Poole K. Efflux mediated multiresistance in Gram-negative bacteria. Clin Microbiol Infect 2004; 10: 12-26.
5. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-40.
6. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81.
7. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011; 35: 736-55.
8. Oh H, Stenhoff S, Jalal S et al. Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains. Microb Drug Res 2003; 9: 323-8.
9. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol 2010; 300: 371-9.
10. Miriagou V, Cornaglia G, Edelstein M et al. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect 2010; 16: 112-22.
11. Martins AF, Zavascki AP, Gaspareto PB et al. Dissemination of Pseudomonas aeruginosa producing SPM-1-like and IMP-1-like metallo-β-lactamases in hospitals from southern Brazil. Infection 2007; 35: 457-60.
12. Castanheira M, Toleman MA, Jones RN et al. Molecular characterization of a β-lactamase gene, blaGIM-1, encoding a new subclass of metallo-β-lactamase. Antimicrob Agents Chemother 2004; 48: 4654-61.
13. Jovcic B, Lepsanovic Z, Suljagic V et al. Emergence of NDM-1 metallo-β-lactamase in Pseudomonas aeruginosa clinical isolates from Serbia. Antimicrob Agents Chemother 2011; 55: 3929-31.
14. Young D, Bell JM, Ritchie B et al. A novel subgroup metallo-β-lactamases (MBL) AIM-1 emerges in Pseudomonas aeruginosa (PSA) from Australia. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract C1-593, p. 75. American Society for Microbiology, Washington, DC, USA.
15. Sevillano E, Gallego L, García-Lobo JM. First detection of the OXA-40 carbapenemase in P. aeruginosa isolates, located on a plasmid also found in A. baumannii. Pathol Biol (Paris) 2009; 57: 493-5.
16. El Garch F, Bogaerts P, Bebrone C et al. OXA-198, an acquired carbapenem-hydrolyzing class D β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 2011; 55: 4828-33.
17. Villegas MV, Lolans K, Correa A et al. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem hydrolyzing β-lactamase. Antimicrob Agents Chemother 2007; 51: 1553-5.
18. Wolter DJ, Kurpiel PM, Woodford N et al. Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. Antimicrob Agents Chemother 2009; 53: 557-62.
19. Poirel L, Weldhagen GF, Naas T et al. GES-2, a class A β-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob Agents Chemother 2001; 45: 2598-603.
20. Viedma E, Juan C, Acosta J et al. Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum β-lactamases GES-1 and GES-5 in Spain. Antimicrob Agents Chemother 2009; 53: 4930-3.
21. Hocquet D, Plésiat P, Dehecq B et al. Nationwide investigation of extended-spectrum β-lactamases, metallo-β-lactamases, and extendedspectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. Antimicrob Agents Chemother 2010; 54: 3512-5.
22. Fothergill JL, Winstanley C, James CE. Novel therapeutic strategies to counter Pseudomonas aeruginosa infections. Expert Rev Anti Infect Ther 2012; 10: 219-35.
23. Paterson DL. Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy. Clin Infect Dis 2008; 15 Suppl 1: S14-20.
24. Mesaros N, Nordmann P, Plésiat P et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007; 13: 560-78.
25. Woodford N, Eastaway AT, Ford M et al. Comparison of BD Phoenix, Vitek2, and MicroScan automated systems for detection and inference of mechanisms responsible for carbapenem resistance in Enterobacteriaceae. J Clin Microbiol 2010; 48: 2999-3002.
26. Micek ST, Lloyd AE, Ritchie DJ et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49: 1306-11.
27. Cantón R, Loza E, Conejo MC et al. Quality control for β-lactam susceptibility testing with a well-defined collection of Enterobacteriaceae and Pseudomonas aeruginosa strains in Spain. J Clin Microbiol 2003; 41: 1912-8.
28. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-first Informational Supplement M100-S21. CLSI, Wayne, PA, USA, 2011.
29. Moya B, Dötsch A, Juan C et al. β-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog 2009; 5: e1000353.
30. Moya B, Zamorano L, Juan C et al. Activity of a new cephalosporin, CXA-101 (FR264205), against β-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother 2010; 54: 1213-7.
31. Peña C, Suarez C, Tubau F et al. Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 β-lactamase. J Clin Microbiol 2009; 47: 2381-7.
32. Juan C, Zamorano L, Pérez JL et al. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 2010; 54: 846-51.
33. Juan C, Mulet X, Zamorano L et al. Detection of the novel extended-spectrum β-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. Antimicrob Agents Chemother 2009; 53: 5288-90.
34. Mulet X, Maciá MD, Mena A et al. Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. Antimicrob Agents Chemother 2009; 53: 1552-60.
35. Mulet X, Moyá B, Juan C et al. Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mechanisms in planktonic but not biofilm growth. Antimicrob Agents Chemother 2011; 55: 4560-8.
36. Juan C, Zamorano L, Mena A et al. Metallo-β-lactamase-producing Pseudomonas putida as a reservoir of multidrug resistance elements that can be transferred to successful Pseudomonas aeruginosa clones. J Antimicrob Chemother 2010; 65: 474-8.
37. Elder BL, Hansen SA, Kellogg JA et al. Cumitech 31, Verification and Validation of Procedures in the Clinical Microbiology Laboratory. McCurdy BW, ed. Washington, DC: American Society for Microbiology, 1997.
38. Poole K. Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2011; 2: 65.
39. Riera E, Cabot G, Mulet X et al. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J Antimicrob Chemother 2011; 66: 2022-7.
40. Cabot G, Ocampo-Sosa AA, Domínguez MA et al. Genetic markers of widespread extensively drug-resistant (XDR) Pseudomonas aeruginosa highrisk clones. Antimicrob Agents Chemother 2012; doi: 10.1128/AAC.01388-12.
41. Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res 2010; 10: 441-51.
42. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. CLSI, Wayne, PA, USA, 2012.
43. Sader HS, Fritsche TR, Jones RN. Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum β-lactam agents. J Clin Microbiol 2006; 44: 1101-4.
44. Juretschko S, Labombardi VJ, Lerner SA et al. Accuracies of β-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek, and Vitek 2). J Clin Microbiol 2007; 45: 1339-42.
45. Livermore DM, Winstanley TG, Shannon KP. Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J Antimicrob Chemother 2001; 48 Suppl 1: 87-102.
46. Courvalin P. Interpretative reading of antimicrobial susceptibility tests. ASM News 1992; 58: 368-75.
47. Torres E, Villanueva R, Bou G. Comparison of different methods of determining β-lactam susceptibility in clinical strains of Pseudomonas aeruginosa. J Med Microbiol 2009; 58: 625-9.
48. Mazzariol A, Aldegheri M, Ligozzi M et al. Performance of Vitek 2 in antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates with different mechanisms of β-lactam resistance. J Clin Microbiol 2008; 46: 2095-8.
49. Winstanley T, Courvalin P. Expert systems in clinical microbiology. Clin Microbiol Rev 2011; 24: 515-56.
50. Leclercq R, Cantón R, Brown DF et al. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 2011; doi:10.1111/j.1469-0691.2011.03703.x.
51. Nordmann P, Naas T. β-lactams and Pseudomonas aeruginosa. In: Courvalin P, Leclercq R, Rice LB, eds. Antibiogram. Washington, DC: ASM Press, 2010; 157-74.
52. Vila J, Marco F. Interpretive reading of the non-fermenting gram-negative bacilli antibiogram. Enferm Infecc Microbiol Clin 2010; 28: 726-36.